The stock of Cara Therapeutics Inc (NASDAQ:CARA) is a huge mover today! About 288,254 shares traded hands. Cara Therapeutics Inc (NASDAQ:CARA) has risen 45.43% since April 26, 2016 and is uptrending. It has outperformed by 40.17% the S&P500.
The move comes after 8 months positive chart setup for the $254.36M company. It was reported on Nov, 29 by Barchart.com. We have $10.54 PT which if reached, will make NASDAQ:CARA worth $15.26M more.
Analysts await Cara Therapeutics Inc (NASDAQ:CARA) to report earnings on March, 9. They expect $-0.51 earnings per share, down 45.71% or $0.16 from last year’s $-0.35 per share. After $-0.42 actual earnings per share reported by Cara Therapeutics Inc for the previous quarter, Wall Street now forecasts 21.43% negative EPS growth.
Cara Therapeutics Inc (NASDAQ:CARA) Ratings Coverage
Out of 5 analysts covering Cara Therapeutics (NASDAQ:CARA), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $32 is the highest target while $20 is the lowest. The $27.40 average target is 175.65% above today’s ($9.94) stock price. Cara Therapeutics has been the topic of 7 analyst reports since July 27, 2015 according to StockzIntelligence Inc. The stock of Cara Therapeutics Inc (NASDAQ:CARA) earned “Buy” rating by Cantor Fitzgerald on Wednesday, November 4. Needham maintained the stock with “Buy” rating in Friday, July 24 report. H.C. Wainwright initiated Cara Therapeutics Inc (NASDAQ:CARA) on Thursday, October 13 with “Buy” rating. Scotia Capital maintained the stock with “Outperform” rating in Thursday, November 24 report.
According to Zacks Investment Research, “Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States.”
Insitutional Activity: The institutional sentiment increased to 1.83 in 2016 Q2. Its up 1.13, from 0.7 in 2016Q1. The ratio increased, as 27 funds sold all Cara Therapeutics Inc shares owned while 20 reduced positions. 6 funds bought stakes while 27 increased positions. They now own 13.15 million shares or 19.13% less from 16.26 million shares in 2016Q1.
Vanguard reported 670,465 shares or 0% of all its holdings. Bancorp Of Montreal Can holds 0% or 180 shares in its portfolio. Opaleye Mngmt Inc holds 1.77% or 675,000 shares in its portfolio. California State Teachers Retirement has 0% invested in the company for 44,054 shares. Bnp Paribas Arbitrage owns 789 shares or 0% of their US portfolio. Franklin Resource has 611,400 shares for 0% of their US portfolio. Bogle Inv Ltd Partnership De last reported 133,545 shares in the company. The Pennsylvania-based Janney Montgomery Scott Lc has invested 0.02% in Cara Therapeutics Inc (NASDAQ:CARA). Schwab Charles Invest Inc holds 27,617 shares or 0% of its portfolio. Manufacturers Life Insurance Communications The last reported 807 shares in the company. Jpmorgan Chase And holds 424,872 shares or 0% of its portfolio. Pictet Asset Management Ltd owns 775,898 shares or 0.02% of their US portfolio. The Connecticut-based Tudor Et Al has invested 0% in Cara Therapeutics Inc (NASDAQ:CARA). Cam Holding A S has invested 0.02% of its portfolio in Cara Therapeutics Inc (NASDAQ:CARA). Wall Street Associate has 0.37% invested in the company for 192,300 shares.
Another recent and important Cara Therapeutics Inc (NASDAQ:CARA) news was published by Streetinsider.com which published an article titled: “Cara Therapeutics (CARA) Completes Enrollment in IV CR845 Phase 2/3 as UP …” on November 29, 2016.
CARA Company Profile
Cara Therapeutics, Inc., incorporated on July 2, 2004, is a clinical-stage biopharmaceutical company. The Firm is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Firm operates through the activities related to the discovery and development of novel therapeutics to treat serious medical conditions, including pain and pruritus segment. The Firm is engaged in developing product candidates that focus on the body’s peripheral nervous system. The Company’s product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.